American Gastroenterological Association Technical Review on the Evaluation of Dyspepsia

Talley, Nicholas J.; Vakil, Nimish B.; Moayyedi, Paul

doi:10.1053/j.gastro.2005.09.020

« Previous Next »Gastroenterology
Volume 129, Issue 5 , Pages 1756-1780, November 2005

American Gastroenterological Association Technical Review on the Evaluation of Dyspepsia

Nicholas J. Talley
- Division of Gastroenterology and Hepatology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota
- Dr. Talley is a consultant for AstraZeneca, Novartis, Axcan, EB Med, Giaconda, Medscape, Solvay, Theravance, and Yamanouchi and received research support from Merck, Novartis, and TAP.
- Address requests for reprints to: Chair, Clinical Practice and Economics Committee, AGA National Office, c/o Membership Department, 4930 Del Ray Avenue, Bethesda, Maryland 20814. Fax: (301) 654-5920.
Nimish B. Vakil
- University of Wisconsin Medical School, Madison, Wisconsin Marquette University College of Health Sciences, Milwaukee, Wisconsin
- Dr. Vakil is a consultant for Meridian Diagnostics, Orexo, and AstraZeneca, and received research support from Janssen, AstraZeneca, and Novartis.
Paul Moayyedi
- McMaster University, Hamilton, Ontario, Canada
- Dr. Moayyedi is a consultant for AstraZeneca, Wyeth Laboratories, and Takeda. His Professorial Chair is also partially funded by an unrestricted donation from AstraZeneca.

This literature review and the recommendations therein were prepared for the American Gastroenterological Association Clinical Practice and Economics Committee. The paper was approved by the Committee on April 22, 2005, and by the AGA Governing Board on October 6, 2005.

Abbreviations used in this paper: CI, confidence interval , DOR, diagnostic odds ratio , EGD, esophagogastroduodenoscopy , GERD, gastroesophageal reflux disease , H₂RA, H₂-receptor antagonist , IBS, irritable bowel syndrome , NNT, number needed to treat , PPI, proton pump inhibitor , RR, relative risk.